Strong growth, margin drag from strategic investments

Delivered 25.7% YoY revenue growth; broad-based across India (7%), International Generics (37%), API (33%)

EBITDA ₹348 Cr / ₹2150 Cr revenue = 16.2% margin; consistent with delivery

Delivered PAT ₹172.4 Cr with 12.2% YoY growth; QoQ PAT fell 14.5% (not disclosed on call)

If reported 49% includes only 1 month of Bosutinib (June launch), base growth ~25% is plausible; consistent with 6-7 launches in Q1

Prior guidance stated low double-digit; new guidance mid-teens if US Generics mid-to-high teens realized; explicit upgrade

Prior: low double-digit (~10-11%); Now: mid-teen (~15%); driven by US Generics outperformance (low-mid-teens → mid-high-teens)

Prior: low to mid-teens; Now: mid to high-teens; Q1 delivered 49% YoY (37% ex-Bosutinib), Bosutinib + 15 more launches planned

Now expected at high single-digit growth (vs prior implied double-digit); management acknowledged 7% Q1 vs market 10%+

Prior: grow ~10% plus/minus; Q1 delivered 33%; Now: 'above 10% level' end of year; guidance lowered from Q1 momentum

Core margins high-teens, offset by 150 bps US branded drag, consolidated ~16-17%; 150 bps dilution as previously guided

Confirmed exclusivity on 100mg, 500mg. Ex-Bosutinib, US grew ~25%, driven by 6-7 new launches in Q1 + some Q4 launches.

Soft launch. Expect positive contribution next financial year onwards. J-curve trajectory: Q1-Q2 heavy investment, sales ramp Q3-Q4, breakeven trend by year-end.

Would like it to be new normal, but have to balance with price erosion. At least next 1-2 quarters should continue this trend.

Tough to say. Exclusivity till November, you'll see Q2 and part of Q3 sales. Over that, if competition enters, will be drastic because volumes very small. Can't really foresee beyond.

Similar Q-o-Q. Guided 70-75% range, sits well within. Factors: Middle East solvent prices up, product mix, debottlenecking maintenance shutdown on Ophthaline (capacity expanded without capex).

Combination of portfolio expansion (farm animals, poultry) and field force productivity. Expect to continue momentum on existing portfolio expansion and operational efficiency.

Will take couple of quarters, work in progress. Going grassroots to territories. Expect positive trends in another quarter or 2.

Trajectory improving, especially Azithral and cough/cold portfolio; traction building.

Gross margins a bit diluted in first half vs last year. Depends on US branded ramp-up whether breakeven Q4 or next year Q1. May be few percentage points and quarters here or there.

Q1 healthy. At end of year, will be above 10% level. Continue growing next couple quarters.

High single-digit growth. Will bridge the gap vs market. Aligned to market this year.

Key is meaningful launches. Have decent pipeline. Even ex-Bosutinib, 15 more launches planned for rest of year, similar number next year. New launches offset erosion, plus branded contribute.

Specialty ~60% of India revenue. Aligned to market on Gynae, Gastro, Ophthal. Driving via quality prescriptions, prescriber consolidation, field productivity.

Will guide for FY28 when we get there. Directionally, operating leverage in core will play out. US branded expected to scale up and contribute to profit, expanding overall margin.

Intangible assets acquired for US branded expansion (product acquisition). Amortized over 7-8 years. Capitalized in Q4, so higher year-on-year. Also added ₹400 Cr capex.

Gross debt ~₹1600 Cr (vs March higher due to higher receivables from sales). Combination of higher debt but lower rates. Working capital should optimize as receivables unwind. Expect to return to March levels minimum and scale down further to 1x EBITDA.

Upgraded based on Q1 US Generics momentum + 15 more launches planned for rest of year; subject to normal market conditions

Q1 delivered 49% YoY (37% ex-Bosutinib); Bosutinib exclusivity ends Nov; pipeline visibility for 15+ launches rest of year

Currently 7% vs market 10%+; new sales head Ramesh Juneja; turnaround expected 1-2 quarters; gap-bridging initiative

Q1 strong; full-year guidance 'above 10%' is vague; likely 10-15% range based on trajectory

Historically grown ~20%; management conservative ('100% achievable'); quarterly variance expected (B2B business)

Operating leverage on higher volumes + capex benefits; Q1 EBITDA margin 16% supports this trajectory

US branded margin dilution guided 100-150 bps for full year; Q1 impact higher than full-year average (ramp-up phase)

Q1 within range despite mix headwind, forex, maintenance shutdown; expected to improve as utilization increases

Added ₹400 Cr capex last year; Ophthaline facility maintenance completed; strategic capex allocation maintained

Bosutinib 180-day exclusivity ends Nov 2026. Only 1 month of sales in Q1. Small-indication product with good pricing but uncertain post-exclusivity sustainability. MD said 'can't really foresee' and '2-player market until Nov'.

India branded at 7% growth vs market ~10-11%. Underperformance in acute segment acknowledged. New sales head Ramesh Juneja hired to drive turnaround, but timing uncertain (1-2 quarters). If turnaround delays, India business could drag consolidated growth.

Q1 gross margins flattish QoQ despite Bosutinib launch. Solvent prices up (Middle East issues), product mix headwind, debottlenecking maintenance on Ophthaline. Within 70-75% guided range but directional pressure.

US branded Pivya in soft-launch phase Q1. Expected margin drag 150 bps full year. Profitability only expected next FY. If ramp-up slower than expected, margin impact could extend or deepen.

Gross debt increased to ₹1600 Cr (vs March) due to higher receivables from strong sales. Interest cost up. Receivables expected to unwind Q2-Q3, but timing uncertain.